Decreased risk of ventricular arrhythmias with treatment of nebivolol in patients with coronary slow flow
Autor: | Koray Celal Demirel, Yilmaz Gunes, Hakki Simsek, Serkan Akdag, Aytac Akyol, Naci Babat, Mehmet Yaman, Ramazan Duz |
---|---|
Rok vydání: | 2016 |
Předmět: |
Adult
Male Risk medicine.medical_specialty 030204 cardiovascular system & hematology QT interval Nebivolol 03 medical and health sciences Coronary circulation 0302 clinical medicine Coronary Circulation Internal medicine Heart rate Humans Medicine In patient medicine.diagnostic_test business.industry Coronary Stenosis Arrhythmias Cardiac Middle Aged medicine.anatomical_structure Blood pressure 030220 oncology & carcinogenesis cardiovascular system Cardiology Population study Female Cardiology and Cardiovascular Medicine business Electrocardiography Blood Flow Velocity medicine.drug |
Zdroj: | Kardiologia Polska. 74:1174-1179 |
ISSN: | 1897-4279 0022-9032 |
Popis: | Background: Coronary slow-flow (CSF) is an angiographic phenomenon characterised by delayed opacification of vessels in the absence of any evidence of obstructive epicardial coronary disease. QT interval dispersion (QTD) reflects regional variations in ventricular repolarisation and cardiac electrical instability and has been reported to be longer in patients with CSF. Aim: To examine QT duration and dispersion in patients with CSF and the effects of nebivolol on these parameters. Methods: The study population included 67 patients with angiographically proven normal coronary arteries and CSF, and 38 patients with angiographically proven normal coronary arteries without associated CSF. The patients were evaluated with 12-lead electrocardiography, and echocardiography before and three months after treatment with nebivolol. Results: Compared to the control group QTcmax and QTcD were significantly longer in patients with CSF (p = 0.036, p = 0.019, respectively). QTcD significantly correlated with the presence of CSF (r = 0.496, p < 0.001). QTcmax (p = 0.027), QTcD (p = 0.002), blood pressure (p = 0.001), and heart rate (p < 0.001) values significantly decreased after treatment with nebivolol. Conclusions: Coronary slow flow is associated with increased QTD. Nebivolol reduced increased QTD in patients with CSF after three months. |
Databáze: | OpenAIRE |
Externí odkaz: |